Optogenetic control of reward-related behaviors
K Deisseroth, I Witten - US Patent 9,992,981, 2018 - Google Patents
Provided herein are compositions and methods for disrupting at least one reward-related
behavior in an individual through the use of light-responsive opsin proteins used to control …
behavior in an individual through the use of light-responsive opsin proteins used to control …
Potential molecular targets in the treatment of lung cancer using siRNA technology
Lung cancer is the leading cause of cancer-related mortality with about 1.6 million deaths
every year worldwide. Gene mutations and overexpression of oncogenes play a central role …
every year worldwide. Gene mutations and overexpression of oncogenes play a central role …
System, method and applications involving identification of biological circuits such as neurological characteristics
K Deisseroth, RD Airan, LA Meltzer - US Patent 9,693,692, 2017 - Google Patents
Various aspects are directed to systems and methods for assessing neural activity of a
neural region having multiple subfields. In certain embodiments, a method includes evoking …
neural region having multiple subfields. In certain embodiments, a method includes evoking …
Thermoresponsive pegylated bubble liposome nanovectors for efficient siRNA delivery via endosomal escape
Aim: Improving the delivery of siRNA into cancer cells via bubble liposomes. Designing a
thermoresponsive pegylated liposome through the introduction of ammonium bicarbonate …
thermoresponsive pegylated liposome through the introduction of ammonium bicarbonate …
Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2
H Kim, SN Danishmalik, H Hwang, JI Sin, J Oh… - Cancer Gene …, 2016 - nature.com
Plasmid DNA-encoded antibodies, or DNA-based monoclonal antibodies (dMAbs), are
delivered by intramuscular injection and in vivo electroporation (EP) and are effective in …
delivered by intramuscular injection and in vivo electroporation (EP) and are effective in …
CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia
U Gamage, K Warnakulasuriya, S Hansika… - Thalassemia …, 2023 - mdpi.com
β-Thalassemia is an inherited hematological disorder that results from genetic changes in
the β-globin gene, leading to the reduced or absent synthesis of β-globin. For several …
the β-globin gene, leading to the reduced or absent synthesis of β-globin. For several …
Gene therapy research in Asia
HX Deng, Y Wang, QR Ding, DL Li, Y Wei - Gene therapy, 2017 - nature.com
Gene therapy has shown great potential for the treatment of diseases that previously were
either untreatable or treatable but not curable with conventional schemes. Recent progress …
either untreatable or treatable but not curable with conventional schemes. Recent progress …
Magnetofection mediated transient NANOG overexpression enhances proliferation and myogenic differentiation of human hair follicle derived mesenchymal stem cells
We used magnetofection (MF) to achieve high transfection efficiency into human
mesenchymal stem cells (MSCs). A custom-made magnet array, matching well-to-well to a …
mesenchymal stem cells (MSCs). A custom-made magnet array, matching well-to-well to a …
Protection is not always a good thing: The immune system's impact on gene therapy
MV Freitas, L Frâncio, L Haleva… - Genetics and molecular …, 2022 - SciELO Brasil
There are many clinical trials underway for the development of gene therapies, and some
have resulted in gene therapy products being commercially approved already. Significant …
have resulted in gene therapy products being commercially approved already. Significant …
scAAV2-Mediated Expression of Thioredoxin 2 and C3 Transferase Prevents Retinal Ganglion Cell Death and Lowers Intraocular Pressure in a Mouse Model of …
HJ Kim, S Cha, JS Choi, JY Lee, KE Kim… - International Journal of …, 2023 - mdpi.com
Elevated intraocular pressure (IOP) in glaucoma causes retinal ganglion cell (RGC) loss and
damage to the optic nerve. Although IOP is controlled pharmacologically, no treatment is …
damage to the optic nerve. Although IOP is controlled pharmacologically, no treatment is …